Centessa Pharmaceuticals plc (CNTA)

Name: Centessa Pharmaceuticals plc (CNTA) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Centessa Pharmaceuticals plc (CNTA)

Stock Card

$40.50

$0.00 (0.00%)

As on 29-Jun-2026 09:30EDT

Market cap

$6,267 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

12.9

Div. Yield

93.8 %

Centessa Pharmaceuticals (CNTA) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 40.50 High: 40.50

52 Week Range

Low: 12.78 High: 40.56

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.6 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.1
Debt to Equity

0.2
Book Value

$--
EPS

$-1.8
Face value

--
Shares outstanding

154,731,309

5 Years Aggregate

CFO

$-514.11 Mln

EBITDA

$-533.58 Mln

Net Profit

$-766.06 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Centessa Pharmaceuticals (CNTA)	61.9	1.7	41.1	208.5	87.5	11.7	--
BSE Sensex^*	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 29-Jun-2026 | *As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Centessa Pharmaceuticals (CNTA)	49.3	109.2	156.8	-72.5
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Centessa Pharmaceuticals (CNTA)	40.5	6,266.6	0.0	-250.6	--	-63.5	--	12.9
Inotiv (NOTV)	0.0	2.8	507.4	-87.0	-9.0	-81.6	--	0.0
Sangamo Therapeutics (SGMO)	0.1	30.7	34.6	-123.3	-358.9	--	--	18.1

Shareholding Pattern

View Details

About Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in... Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Read more

CEO & Director

Dr. Saurabh Saha M.D., Ph.D.
CEO & Director

Dr. Saurabh Saha M.D., Ph.D.
Headquarters

Altrincham
Website

https://centessa.com

FAQs for Centessa Pharmaceuticals (CNTA)

What is the current share price of Centessa Pharmaceuticals plc (CNTA) Today?

The share price of Centessa Pharmaceuticals plc (CNTA) is $40.50 (NASDAQ) as of 29-Jun-2026 09:30 EDT. Centessa Pharmaceuticals plc (CNTA) has given a return of 87.54% in the last 3 years.

What is the current PB & PE ratio of Centessa Pharmaceuticals plc (CNTA)?

Since, TTM earnings of Centessa Pharmaceuticals plc (CNTA) is negative, P/E ratio is not available.
The P/B ratio of Centessa Pharmaceuticals plc (CNTA) is 12.86 times as on 29-Jun-2026, a 148 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-17.18	6.44
2024	-9.38	5.51
2023	-5.16	3.30
2022	-1.36	0.87
2021	-2.65	2.06

What is the 52 Week High and Low of Centessa Pharmaceuticals plc (CNTA)?

The 52-week high and low of Centessa Pharmaceuticals plc (CNTA) are Rs 40.56 and Rs 12.78 as of 05-Sep-2026.

What is the market cap of Centessa Pharmaceuticals plc (CNTA)?

Centessa Pharmaceuticals plc (CNTA) has a market capitalisation of $ 6,267 Mln as on 29-Jun-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Centessa Pharmaceuticals plc (CNTA)?

Before investing in Centessa Pharmaceuticals plc (CNTA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.